How to Save $100 Billion
The Pharmaceutical Care Management Association (PCMA) sent a letter to the Joint Select Committee on Deficit Reduction that outlined greater use of pharmacy benefit management (PBM) tools to save more than $100 billion in prescription drug costs over the next 10 years.
The Pharmaceutical Care Management Association (PCMA) sent a letter to the Joint Select Committee on Deficit Reduction that outlined greater use of pharmacy benefit management (PBM) tools to save more than $100 billion in prescription drug costs over the next 10 years.
“Policymakers looking for savings solutions should consider modernizing Medicaid pharmacy,” says Charles Cote PCMA assistant vice president, Strategic Communications. “Currently, the Medicaid fee-for-service program uses fewer generic drugs and pays drugstores more than double the pharmacy fees that Medicare or private insurers pay. Over the next decade, the federal government alone could save $21 billion - without cutting benefits or payments to doctors and hospitals - by modernizing Medicaid pharmacy benefits and utilizing proven PBM tools.”
In addition to modernizing Medicaid pharmacy, the options PCMA recommended to the Joint Select Committee included maximizing generic and therapeutic substitution in Part D, expediting the approval of biogenerics, allowing Part D plans to negotiate greater discounts on all drugs, banning a tax deduction for direct-to-consumer drug advertising, encouraging chronic care pharmacy and home delivery, and banning pay-for-delay drug settlements between brand-name drug companies and generic manufacturers.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
